BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
0.00 (0.00%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 55.04 - 84.25
Open     -
Vol / Avg. 400.00/1.12M
Mkt cap 9.02B
P/E     -
Div/yield     -
EPS -1.23
Shares 145.93M
Beta 0.92
Inst. own 102%
Oct 22, 2014
Q3 2014 Biomarin Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 30, 2014
Q2 2014 Biomarin Pharmaceutical Inc Earnings Call
Jul 30, 2014
Q2 2014 BioMarin Pharmaceutical Inc. Earnings Release
Jun 17, 2014
Biomarin Pharmaceutical Inc at Wells Fargo Healthcare Conference
Jun 4, 2014
BioMarin Pharmaceutical Inc. Annual Shareholder Meeting
May 20, 2014
BioMarin Pharmaceutical Inc. at UBS Global Healthcare Conference
May 14, 2014
BioMarin Pharmaceutical Inc. at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -25.15% -32.15%
Operating margin -17.46% -30.81%
EBITD margin - -18.93%
Return on average assets -6.67% -9.25%
Return on average equity -10.92% -14.97%
Employees 1,341 -
CDP Score - -


NOVATO, CA 94949
United States - Map
+1-415-5066700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company�s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.

Officers and directors

Pierre Lapalme Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 59
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Dennis J. Slamon M.D., Ph.D. Director
Age: 65
Bio & Compensation  - Reuters